Last reviewed · How we verify
Tacrolimus withdrawal
Tacrolimus withdrawal is a Small molecule drug developed by University of Wisconsin, Madison. It is currently FDA-approved.
Tacrolimus is used to treat various conditions including liver transplantation, kidney diseases, and graft vs host disease, and works by inhibiting the peptidyl-prolyl cis-trans isomerase FKBP1A. Withdrawal of tacrolimus has been studied in clinical trials for conditions such as liver transplantation and kidney diseases, often in combination with other immunosuppressive medications.
At a glance
| Generic name | Tacrolimus withdrawal |
|---|---|
| Sponsor | University of Wisconsin, Madison |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- Tocilizumab in Cardiac Transplantation (PHASE2)
- REgulatory T Cell Therapy to Achieve Immunosuppression REduction (PHASE2)
- EVR and EPO for Liver Transplant Tolerance (PHASE1)
- CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial (PHASE3)
- Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants (PHASE1)
- Belatacept in Heart Transplantation (PHASE2)
- Expanding Liver Transplant Immunosuppression Minimization Via Everolimus (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Tacrolimus withdrawal CI brief — competitive landscape report
- Tacrolimus withdrawal updates RSS · CI watch RSS
- University of Wisconsin, Madison portfolio CI
Frequently asked questions about Tacrolimus withdrawal
What is Tacrolimus withdrawal?
Who makes Tacrolimus withdrawal?
What development phase is Tacrolimus withdrawal in?
Related
- Manufacturer: University of Wisconsin, Madison — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing